Community Acquired Pneumonia Due to Mycoplasma pneumoniae versus Non-Mycoplasma Pneumoniae: A Comparative Analysis from a Tertiary Care Hospital
Asian Journal of Research in Infectious Diseases,
Aims: The study aims to compare the clinical and microbiological profile in adult, hospitalised patients of community acquired pneumonia due to Mycoplasma pneumoniae (MP) vs other bacterial agents.
Study Design: Prospective, observational study.
Place and Duration of Study: Study was carried out in Department of Microbiology, Kasturba Medical College, Manipal in a span of eighteen months (August 2014 to February 2016).
Methodology: A Hospital based study in a tertiary care center was conducted. Adult hospitalised patients suspected of community acquired pneumonia (according to IDSA guidelines) were included in the study. Cases with immunosuppression and prior hospital admission were excluded. Respiratory samples were collected and cultured for all the studied cases. PCR was performed for the detection of Mycoplasma pneumoniae by targeting P1 gene.
Results: The study cases (n=140) had mean age of 57 years and mean hospital stay of 7 days, comprising 67.6% males and 32.4% females. Amongst all the cases of CAP that were included in the study, Mycoplasma pneumoniae was detected in 23(16.4%) cases with 12 (52.2%) cases due to MP alone and 11 cases (47.8%) had multiple bacterial etiology. Symptoms such as chest pain (91.7%), joint pains (45.8%), earache (41.7%) and sepsis (56.5%) were significantly higher (p<0.005) when Mycoplasma pneumonia was the detected pathogen. Moreover worsening of clinical condition and mortality was also observed higher in this group.
Conclusion: Association of higher morbidity and mortality, as observed in current study, highlights the importance of early and timely diagnosis of Mycoplasma pneumoniae in hospitalized patients with community-acquired pneumonia.
- Mycoplasma pneumoniae
- multiplex PCR
How to Cite
Marston BJ, Plouffe JF, File TM, Hackman BA, Salstrom SJ, Lipman HB, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Archives of Internal Medicine. 1997;157(15):1709-18.
Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clinical Microbiology Reviews. 2004;17(4):697-728.
Bansal S, Kashyap S, Pal l, Goel A. Clinical and bacteriological profile of community acquired pneumonia in Shimla, Himachal Pradesh. Indian Journal of Chest Diseases and Allied Sciences. 2004;46(1): 17-22.
Oberoi A, Aggarwal A. Bacteriological profile, serology and antibiotic sensitivity pattern of Micro-organisms from community acquired pneumonia; 2006.
Chaudhry R, Nazima N, Dhawan B, Kabra S. Prevalence of Mycoplasma pneumoniae andchlamydia pneumoniae in children with community acquired pneumonia. The Indian Journal of Pediatrics. 1998;65(5): 717-21.
Kraft M, Cassell GH, Henson JE, Watson H, Williamson J, Marmion B, et al. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. American Journal of Respiratory and Critical Care Medicine. 1998;158(3):998-1001.
Gadsby NJ, Russell CD, Mchugh MP, Mark H, Morris AC, Laurenson IF, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clinical Infectious Diseases. 2016;civ1214.
Chaudhry R, Sharma S, Javed S, Passi K, Dey A, Malhotra P. Molecular detection of mycoplasma Pneumoniae by quantitative real-time PCR in patients with community acquired pneumonia. Indian Journal of Medical Research. 2013; 138(2):244.
Saraya T, Kurai D, Nakagaki K, Sasaki Y, Niwa S, Tsukagoshi H, et al. Novel aspects on the pathogenesis of mycoplasma pneumoniae pneumonia and therapeutic implications. Frontiers in Microbiology. 2014;5:410.
Loconsole D, De Robertis AL, Mallamaci R, Sallustio A, Morea A, Prato R, Quarto M, Martinelli D, Chironna M. First description of macrolide-resistant Mycoplasma pneumoniae in adults with community-acquired pneumonia in Italy. Biomed Research International; 2019.
Varma-Basil M, Dwivedi SK, Kumar K, Pathak R, Rastogi R, Thukral S, et al. Role of mycoplasma pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease. Journal of Medical Microbiology. 2009;58(3):322-6.
Kashyap S, Sarkar M. Mycoplasma pneumonia: Clinical features and management. Lung India: Official Organ of Indian Chest Society. 2010;27(2):75.
Nilsson AC, Björkman P, Welinder-Olsson C, Widell A, Persson K. Clinical severity of Mycoplasma pneumoniae (MP) infection is associated with bacterial load in oropharyngeal secretions but not with mp genotype. BMC Infectious Diseases. 2010; 10(1):39.
Miyashita N, Obase Y, Ouchi K, Kawasaki K, Kawai Y, Kobashi Y, et al. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. Journal of Medical Microbiology. 2007;56(12): 1625-9.
Talkington DF, Waites KB, Schwartz SB, Besser R. Emerging from obscurity: understanding pulmonary and extrapulmonary syndromes, pathogenesis, and epidemiology of human Mycoplasma pneumoniae infections. Emerging Infections. 2001;57-84.
Ali N, Sillis M, Andrews B, Jenkins P, Harrison B. The clinical spectrum and diagnosis of Mycoplasma pneumoniae infection. QJM. 1986;58(3-4):241-51.
Drasbek M, Nielsen PK, Persson K, Birkelund S, Christiansen G. Immune response to Mycoplasma pneumoniae p1 and p116 in patients with atypical pneumonia analyzed by Elisa. BMC Microbiology. 2004;4(1):7.
Chen YC, Hsu WY, Chang TH. Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia. Emerging Infectious Diseases. 2020;26(7):1382.
Abstract View: 61 times
PDF Download: 16 times